Trial
NCT00983528
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, San Diego
Collaborators
Genzyme, a Sanofi Company
Condition
Acute Lymphoblastic Leukemia
Intervention
Alemtuzumab
Why stopped
Support withdrawn due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-12